Abstract:
Bronchopulmonary dysplasia (BPD) is the leading cause of longterm respiratory disability among prematurely born infants and is a significant contributor to life-long neurodevelopmental problems. Affected infants are often exposed to a myriad of pharmacologic agents. In the neonatal intensive care unit. Many of these drugs are off label and have limited efficacy and significant toxicity. They include diuretics, bronchodilators, and agents to treat presumed gastro-esophageal reflux. This presentation will summarize the pulmonary injury sequence and the epidemiology of BPD. Various pharmacologic agents will be reviewed and evidence will be presented to balance their efficacy and safety. The presentation will conclude with a glimpse into evolving treatments
